ID   K562/FLM
AC   CVCL_E7CM
RX   PubMed=39046364;
CC   Population: Caucasian.
CC   Characteristics: Resistant to about 50 nmol/L of flumatinib. Also resistant to imatinib and doxorubicin (PubMed=39046364).
CC   Selected for resistance to: ChEBI; CHEBI_233593; Flumatinib.
CC   Sequence variation: Gene fusion; HGNC; HGNC:76; ABL1 + HGNC; HGNC:1014; BCR; Name(s)=BCR-ABL1, BCR-ABL; Note=BCR exon 14 fused to ABL1 exon 2 (b3a2 transcript) (PubMed=39046364).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 10-04-25; Last updated: 10-04-25; Version: 1
//
RX   PubMed=39046364; DOI=10.1111/jcmm.18539; PMCID=PMC11267979;
RA   Huang J.-X., Xiao J., He L.-F., Dai W.-J., Xiao J., Li Y.-Q., He Y.,
RA   Yu L.;
RT   "Overcoming flumatinib resistance in chronic myeloid leukaemia:
RT   Insights into cellular mechanisms and ivermectin's therapeutic
RT   potential.";
RL   J. Cell. Mol. Med. 28:e18539.1-e18539.10(2024).
//